05.07.2022 14:32:11
|
Dyne Therapeutics: FDA Clears IND Application To Initiate Clinical Trial Of DYNE-251
(RTTNews) - Dyne Therapeutics, Inc. (DYN) announced the FDA has lifted the clinical hold and cleared the company's Investigational New Drug application to begin a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. The company expects to begin dosing patients in a phase 1/2 trial evaluating DYNE-251 in mid-2022.
Dyne Therapeutics said the trial aims to enroll 30 to 50 ambulant and non-ambulant males with Duchenne, who are age 4 to 16 and have mutations amenable to exon 51 skipping therapy.
Shares of Dyne Therapeutics are up 9% in pre-market trade on Tuesday.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dynegy Incmehr Nachrichten
Keine Nachrichten verfügbar. |